415 related articles for article (PubMed ID: 29150411)
1. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.
Maher TM; Oballa E; Simpson JK; Porte J; Habgood A; Fahy WA; Flynn A; Molyneaux PL; Braybrooke R; Divyateja H; Parfrey H; Rassl D; Russell AM; Saini G; Renzoni EA; Duggan AM; Hubbard R; Wells AU; Lukey PT; Marshall RP; Jenkins RG
Lancet Respir Med; 2017 Dec; 5(12):946-955. PubMed ID: 29150411
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.
Jenkins RG; Simpson JK; Saini G; Bentley JH; Russell AM; Braybrooke R; Molyneaux PL; McKeever TM; Wells AU; Flynn A; Hubbard RB; Leeming DJ; Marshall RP; Karsdal MA; Lukey PT; Maher TM
Lancet Respir Med; 2015 Jun; 3(6):462-72. PubMed ID: 25770676
[TBL] [Abstract][Full Text] [Related]
3. Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias.
White ES; Xia M; Murray S; Dyal R; Flaherty CM; Flaherty KR; Moore BB; Cheng L; Doyle TJ; Villalba J; Dellaripa PF; Rosas IO; Kurtis JD; Martinez FJ
Am J Respir Crit Care Med; 2016 Nov; 194(10):1242-1251. PubMed ID: 27149370
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease.
Doubková M; Karpíšek M; Mazoch J; Skřičková J; Doubek M
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Oct; 33(3):224-234. PubMed ID: 27758987
[TBL] [Abstract][Full Text] [Related]
5. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.
Ikeda K; Chiba H; Nishikiori H; Azuma A; Kondoh Y; Ogura T; Taguchi Y; Ebina M; Sakaguchi H; Miyazawa S; Suga M; Sugiyama Y; Nukiwa T; Kudoh S; Takahashi H;
Respir Res; 2020 Nov; 21(1):316. PubMed ID: 33256760
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous T-cell-attracting chemokine as a novel biomarker for predicting prognosis of idiopathic pulmonary fibrosis: a prospective observational study.
Niwamoto T; Handa T; Murase Y; Nakatsuka Y; Tanizawa K; Taguchi Y; Tomioka H; Tomii K; Kita H; Uyama M; Tsuchiya M; Emura M; Kawamura T; Arai N; Arita M; Uno K; Yoshizawa A; Uozumi R; Yamaguchi I; Matsuda F; Chin K; Hirai T
Respir Res; 2021 Jun; 22(1):181. PubMed ID: 34158044
[TBL] [Abstract][Full Text] [Related]
7. Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis.
Hamai K; Iwamoto H; Ishikawa N; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Ohshimo S; Fujitaka K; Hamada H; Hattori N; Kohno N
Dis Markers; 2016; 2016():4759040. PubMed ID: 27293304
[TBL] [Abstract][Full Text] [Related]
8. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis.
Tzouvelekis A; Herazo-Maya JD; Slade M; Chu JH; Deiuliis G; Ryu C; Li Q; Sakamoto K; Ibarra G; Pan H; Gulati M; Antin-Ozerkis D; Herzog EL; Kaminski N
Respirology; 2017 Apr; 22(3):486-493. PubMed ID: 27761978
[TBL] [Abstract][Full Text] [Related]
9. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.
Kinder BW; Brown KK; McCormack FX; Ix JH; Kervitsky A; Schwarz MI; King TE
Chest; 2009 Jun; 135(6):1557-1563. PubMed ID: 19255294
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.
Richards TJ; Kaminski N; Baribaud F; Flavin S; Brodmerkel C; Horowitz D; Li K; Choi J; Vuga LJ; Lindell KO; Klesen M; Zhang Y; Gibson KF
Am J Respir Crit Care Med; 2012 Jan; 185(1):67-76. PubMed ID: 22016448
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.
Kennedy B; Branagan P; Moloney F; Haroon M; O'Connell OJ; O'Connor TM; O'Regan K; Harney S; Henry MT
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):228-36. PubMed ID: 26422568
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis.
Sokai A; Handa T; Tanizawa K; Oga T; Uno K; Tsuruyama T; Kubo T; Ikezoe K; Nakatsuka Y; Tanimura K; Muro S; Hirai T; Nagai S; Chin K; Mishima M
Respir Res; 2015 Sep; 16():120. PubMed ID: 26415518
[TBL] [Abstract][Full Text] [Related]
13. Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Wang K; Ju Q; Cao J; Tang W; Zhang J
Medicine (Baltimore); 2017 Jun; 96(23):e7083. PubMed ID: 28591049
[TBL] [Abstract][Full Text] [Related]
14. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis.
Song JW; Do KH; Jang SJ; Colby TV; Han S; Kim DS
Chest; 2013 May; 143(5):1422-1429. PubMed ID: 23715088
[TBL] [Abstract][Full Text] [Related]
15. Effect of single vs bilateral lung transplantation on plasma surfactant protein D levels in idiopathic pulmonary fibrosis.
Sims MW; Beers MF; Ahya VN; Kawut SM; Sims KD; Lederer DJ; Palmer SM; Wille K; Lama VN; Shah PD; Orens JB; Bhorade S; Crespo M; Weinacker A; Demissie E; Bellamy S; Christie JD; Ware LB;
Chest; 2011 Aug; 140(2):489-496. PubMed ID: 21349925
[TBL] [Abstract][Full Text] [Related]
16. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis.
Adegunsoye A; Alqalyoobi S; Linderholm A; Bowman WS; Lee CT; Pugashetti JV; Sarma N; Ma SF; Haczku A; Sperling A; Strek ME; Noth I; Oldham JM
Chest; 2020 Oct; 158(4):1526-1534. PubMed ID: 32450241
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers.
Raghu G; Richeldi L; Jagerschmidt A; Martin V; Subramaniam A; Ozoux ML; Esperet CA; Soubrane C
Chest; 2018 Dec; 154(6):1359-1370. PubMed ID: 30526970
[TBL] [Abstract][Full Text] [Related]
18. The significance of elevated tumor markers among patients with idiopathic pulmonary fibrosis before and after lung transplantation.
Rusanov V; Kramer MR; Raviv Y; Medalion B; Guber A; Shitrit D
Chest; 2012 Apr; 141(4):1047-1054. PubMed ID: 21940773
[TBL] [Abstract][Full Text] [Related]
19. CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort.
Molyneaux PL; Fahy WA; Byrne AJ; Braybrooke R; Saunders P; Toshner R; Albers G; Chua F; Renzoni EA; Wells AU; Karkera Y; Oballa E; Saini G; Nicholson AG; Jenkins RG; Maher TM
Am J Respir Crit Care Med; 2022 Jun; 205(12):1440-1448. PubMed ID: 35363592
[No Abstract] [Full Text] [Related]
20. Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis.
Jessen H; Hoyer N; Prior TS; Frederiksen P; Rønnow SR; Karsdal MA; Leeming DJ; Bendstrup E; Sand JMB; Shaker SB
BMC Pulm Med; 2021 Nov; 21(1):382. PubMed ID: 34814865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
